Skip to Content
New To Chronic Myeloid Leukemia? Get Information Today >>

Idarubicin Pregnancy and Breastfeeding Warnings

Idarubicin is also known as: Idamycin, Idamycin PFS

Idarubicin Pregnancy Warnings

Idarubicin has been assigned to pregnancy category D by the FDA. Animal data have revealed evidence of teratogenicity, embryotoxicity, testicular atrophy, and inhibition of spermatogenesis and sperm maturation. There is no conclusive information about idarubicin adversely affecting human fertility or causing teratogenesis. There are no adequate and well-controlled studies in pregnant women. If idarubicin is to be used during pregnancy, or if the patient becomes pregnant during therapy, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid pregnancy. Use of idarubicin during pregnancy is considered contraindicated.

A single case in which idarubicin was given during pregnancy has been reported. Data are available for other anthracyclines. A 26-year-old woman presented at 20 weeks' gestation with acute myelogenous leukemia (AML) received daunorubicin and cytarabine as induction therapy, but required retreatment after 3 weeks due to unequivocal evidence of persistence of acute leukemia. She received mitoxantrone and cytarabine as her second course of chemotherapy. Complete remission and a normal fetal growth rate were documented after a total of 60 days from the start of therapy. Due to the long period of time required to obtain remission, it was decided to consolidate therapy with idarubicin 10 mg/m2 (with cytarabine) at approximately 32 weeks' gestation. She tolerated the treatment well and was discharged only to return two days later complaining of abdominal pain and lack of fetal activity for six to eight hours. After ultrasonographic evidence of fetal death, labor was induced, and the patient delivered a stillborn fetus with no obvious congenital malformations weighing 2,200 grams. Autopsy permission was denied. Limited data have shown that it is possible to give a single very high dose cycle of chemotherapy for AML in younger women without compromising fertility.

See references

Idarubicin Breastfeeding Warnings

There are no data on the excretion of idarubicin into human milk. Because many drugs are excreted into human milk and because the potential for serious adverse reactions in nursing infants from idarubicin, mothers should discontinue nursing prior to taking this drug.

See references

References for pregnancy information

  1. Cantini E, Yanes B "Acute myelogenous leukemia in pregnancy." South Med J 77 (1984): 1050-2
  2. Feliu J, Juarez S, Ordonez A, Garcia-Paredes ML, Gonzalez-Baron M, Montero JM "Acute leukemia and pregnancy." Cancer 61 (1988): 580-4
  3. Kamiguchi Y, Tateno H, Iizawa Y, Mikamo K "Chromosome analysis of human spermatozoa exposed to antineoplastic agents in vitro." Mutat Res 326 (1995): 185-92
  4. Nicholson HO "Cytotoxic drugs in pregnancy: review of reported cases." J Obstet Gynaecol Br Commonw 75 (1968): 307-12
  5. Schafer AI "Teratogenic effects of antileukemic chemotherapy." Arch Intern Med 141 (1981): 514-5
  6. Okun DB, Groncy PK, Sieger L, Tanaka KR "Acute leukemia in pregnancy: transient neonatal myelosuppression after combination chemotherapy in the mother." Med Pediatr Oncol 7 (1979): 315-9
  7. Russell JA, Powles RI, Oliver RT "Conception and congenital abnormalities after chemotherapy of acute myelogenous leukemia in two men." Br Med J 1 (1976): 1508
  8. O'Donnell R, Costigan C, O'Connell LG "Two cases of acute leukaemia in pregnancy." Acta Haematol 61 (1979): 298-300
  9. Estiu M "Successful pregnancy in leukemia." Lancet 1 (1977): 433
  10. Reynoso EE, Huerta F "Acute leukemia and pregnancy--fatal fetal outcome after exposure to idarubicin during the second trimester." Acta Oncol 33 (1994): 709-10
  11. Gililland J, Weinstein L "The effects of cancer chemotherapeutic agents on the developing fetus." Obstet Gynecol Surv 38 (1983): 6-13
  12. Salooja N, Chatterjee R, McMillan AK, Kelsey SM, Newland AC, Milligan DW, Franklin IM, Hutchinson RM, Linch DC, Goldstone AH "Successful pregnancies in women following single autotransplant for acute myeloid leukemia with a chemotherapy ablation protocol." Bone Marrow Transplant 13 (1994): 431-5
  13. Tobias JS, Bloom HJ "Doxorubicin in pregnancy." Lancet 1 (1980): 776
  14. Griffiths M "Acute leukaemia during pregnancy." Lancet 1 (1988): 586
  15. Artlich A, Moller J, Tschakaloff A, Schwinger E, Kruse K, Gortner L "Teratogenic effects in a case of maternal treatment for acute myelocytic leukaemia--neonatal and infantile course." Eur J Pediatr 153 (1994): 488-91
  16. Dobbing J "Pregnancy and leukemia." Lancet 1 (1977): 1155
  17. Morishita S, Imai A, Kawabata I, Tamaya T "Acute myelogenous leukemia in pregnancy: fetal blood sampling and early effects of chemotherapy." Int J Gynaecol Obstet 44 (1994): 273-7
  18. Valemzuela PL, Montalban C, Matorras R, Nieto A, Gonzales A, Perera S "Pregnancy and relapse of peripheral T cell lymphoma. A case report." Gynecol Obstet Invest 32 (1991): 59-61
  19. Lowenthal RM, Marsden KA, Newman NM, Baikie MJ, Campbell SN "Normal infant after treatment of acute myeloid leukaemia in pregnancy with daunorubicin." Aust N Z J Med 8 (1978): 431-2
  20. Doney KC, Kraemer KG, Shepard TH "Combination chemotherapy for acute myelocytic leukemia during pregnancy: three case reports." Cancer Treat Rep 63 (1979): 369-71
  21. Hamer JW, Beard ME, Duff GB "Pregnancy complicated by acute myeloid leukemia." N Z Med J 89 (1979): 212-3
  22. Alegre A, Chunchurreta R, Rodriguez-Alarcon J, Cruz E, Prada M "Successful pregnancy in acute promyelocytic leukemia." Cancer 49 (1982): 152-3
  23. Turchi JJ, Villasis C "Anthracyclines in the treatment of malignancy in pregnancy." Cancer 61 (1988): 435-40
  24. Sanz MA, Rafecas FJ "Successful pregnancy during chemotherapy for acute promyelocytic leukemia." N Engl J Med 306 (1982): 939
  25. Volkenandt M, Buchner T, Hiddemann W, van de Loo J "Acute leukaemia during pregnancy." Lancet 2 (1987): 1521-2
  26. Gokal R, Durrant J, Baum JD, Bennett MJ "Successful pregnancy in acute monocytic leukaemia." Br J Cancer 34 (1976): 299-302
  27. Lilleyman JS, Hill AS, Anderton KJ "Consequences of acute myelogenous leukemia in early pregnancy." Cancer 40 (1977): 1300-3
  28. Sears HF, Reid J "Granulocytic sarcoma: local presentation of a systemic disease." Cancer 37 (1976): 1808-13
  29. Schleuning M, Clemm C "Chromosomal aberrations in a newborn whose mother received cytotoxic treatment during pregnancy." N Engl J Med 317 (1987): 1666-7
  30. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 5th ed." Baltimore, MD: Williams & Wilkins (1998):
  31. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  32. Matthews JH, Wood JK "Male fertility during chemotherapy for acute leukemia." N Engl J Med 303 (1980): 1235

References for breastfeeding information

  1. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.